Insightec’s Exablate Neuro provides an incisionless treatment option for essential tremour and tremour-dominant Parkinson’s disease patients. Credit: Marvin 101.

Israel-based medical technology company Insightec has signed a definitive agreement for funding of about $150m to support continued research to evaluate focused ultrasound for the treatment of certain movement disorders.

Series F financing at a post-money valuation of $1.3bn is led by Koch Industries’ subsidiary Koch Disruptive Technologies (KDT), which has committed to invest $100m at an initial closing to follow shareholder approval.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

This is the second direct investment by the company in Insightec.

In 2016, Insightec obtained the US Food and Drug Administration (FDA) approval for its Exablate Neuro system for the treatment of certain movement disorders in patients with essential tremor and tremor-dominant Parkinson’s disease.

Exablate incisionless neurosurgery platform is the first MR-guided ultrasound device.

Insightec CEO and Board chairman Maurice Ferré said: “Our partnership with KDT and other investors is helping to fuel our momentum as a rapidly growing number of medical institutions adopt our focused ultrasound technology. This new investment demonstrates our investors’ commitment to help drive the next generation of focused ultrasound.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Exablate Neuro system is said to facilitate an immediate tremor improvement after the outpatient procedure. It promises minimal risk of infection, bleeding or other surgical complications.

Koch Disruptive Technologies president Chase Koch said: “Insightec’s focused ultrasound technology is disrupting the way surgery has been performed for generations. KDT is focused on empowering innovative companies and helping them realise their potential to improve the lives of millions of people.”

Insightec states that around 65 medical centres across the world have adopted the system to treat patients with essential tremor.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact